Bristol Myers signals 2026 non-GAAP EPS $6.35-$6.55 while preparing for $1.5B-$2B Eliquis step-down in 2027

Bristol Myers Squibb Q3 2026 earnings: raised guidance, strong Eliquis growth, and key pipeline catalysts ahead.